QPS Celebrates 30th Anniversary
Article content
NEWARK, Del. — QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalytics and clinical trials, is celebrating its 30-year anniversary in 2025. Founded by Dr. Benjamin Chien in 1995 to provide high-quality bioanalytical liquid chromatography with tandem mass spectrometry (LC-MS/MS) contract services, QPS is now recognized as a global leader in contract research. Over the past 30 years, the company has grown from a single office in Delaware, USA to a widely respected, global, full-service CRO with 8 locations spread across the US, EU, Asia, India and Australia, a clinical trial network of over 700 sites and an increased focus on leveraging the power of AI to accelerate clinical trials.
Article content
QPS Holdings, LLC celebrates 30 years of excellence providing preclinical, bioanalysis and clinical contract research organization services.
Article content
Over the years, QPS has grown from a small molecule bioanalysis shop of three people to a global CRO with more than 1,200 employees. '30 years is a major milestone for QPS and I couldn't be more proud of the hard-working and innovative people who choose to work at QPS. They are the backbone of the company, and I am very grateful for their valuable contributions,' said founder and CEO of QPS, Dr. Benjamin Chien.
Article content
'Through QPS, the pharmaceutical and biotechnology industries have access to dedicated, focused scientific expertise across the drug development spectrum. In facilities around the world, QPS has assembled best-in-class instruments, platforms, people and processes required to conduct the studies necessary to support client drug discovery and development programs focused on obesity, type 2 diabetes, oncology, CNS diseases, cell and gene therapy, and more,' said Dr. Chien.
Article content
Since its humble beginnings, QPS has expanded its service options, to include pharmacology, DMPK, toxicology, bioanalysis, translational medicine, leukopaks, PBMCs, cell therapy products, clinical trials, central lab services, and a full range of clinical research services.
Article content
QPS is known for high-quality data, technical expertise, delivery of promised study timelines, collaborative solutions, and customer-focused strategies. Going forward, QPS plans to continue delivering custom-built research services that accelerate pharmaceutical breakthroughs across the globe.
Article content
ABOUT QPS HOLDINGS, LLC
Article content
QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, Asia and Australia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, leukopaks, PBMCs and cell therapy products, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.
Article content
Article content
Article content
Article content
QPS CONTACT:
Article content
Article content
Name:
Article content
Gabrielle Pastore
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
30 minutes ago
- Globe and Mail
1 Under-the-Radar and Undervalued Stock Investors Can Buy Now in June
This company is well positioned to benefit from the sustained increase in e-commerce spending over the long term. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » *Stock prices used were the afternoon prices of June 4, 2025. The video was published on June 6, 2025. Should you invest $1,000 in Paccar right now? Before you buy stock in Paccar, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Paccar wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor 's total average return is997% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.
National Post
44 minutes ago
- National Post
Raymond J. de Souza: This Trump-Musk cage match could be seen coming
WASHINGTON, D.C. — More or less on schedule, U.S. President Donald Trump and Elon Musk are headed for a steel cage match. The steel will be more expensive now due to tariffs, but spectacles don't come cheap. Article content This past week's Trump-Musk breakup could be dismissed as simply the latest episode of a professional-wrestling-reality-show presidency. The script is as old as baby-oiled wrestlers in the ring and as current as the Axe-body-sprayed young men in the audience. Article content Article content Article content Two great titans — The World's Richest Man™ and The World's Most Powerful Man™ — joined forces to form a fearsome tag-team. Call the alliance The World's Most Manly Men™, with rotating mouthpiece managers in their corner, Joe Rogan, Tucker Carlson and the like. Article content Article content The World's Most Manly Men™ steamroller over weak opponents at first to establish their dominance. Trump-Musk dismantle overseas aid to the poor; Trump-Musk take down funding for Aids prevention and treatment in Africa. Next up, The World's Most Manly Men™ grapple with stronger opponents, preferably effete and somehow suspect; Trump-Musk battle public broadcasting, then Columbia, then Harvard. Article content Eventually though, the new tag-team champions run into formidable opponents — the judiciary, the bond market, the American voter's preference for big government without having to pay for it. Victory is no longer easy nor assured. Will The World's Most Manly Men™ prevail? Article content The final step comes as surely as celebrities gather like moths around the pro-wrestling flame. The World's Most Manly Men™ must turn on each other. The spittle-flecked air is filled with cries of ingratitude, betrayal and treachery. The ambush then comes. The allies turn on each other. A low blow is landed — Trump is a reckless spendthrift! A steel chair is used to devastating effect — Musk's government subsidies will be cut off! Article content Article content The erstwhile allies are headed for a showdown. Tickets are sold to the clash of the titans; The World's Most Manly Men™ will fight each other in a cage match. Article content Article content That may well suffice as an explanation for the latest melodrama here in Washington, the latest staging of circuses in the declining imperial capital. But it overlooks a deeper division at the heart of the Trump project, a division advertised as brazenly as the golden Trump brand on a failed casino or a skip-the-line visa. It was right there in the name: Department of Government Efficiency (DOGE). Article content Efficiency is what Elon Musk desires, but it runs counter to the heart of the Trump project. Efficiency is what has driven globalization, automation, information technology and open trade, where more efficient production enables cheaper goods and services. Efficiency is the altar at which Musk and the tech-bros worship. Efficiency is the AI future where goods are cheap and services may well be cheaper still; The World's Most Richest Man™ takes his billions and employment shrinks dramatically.
Globe and Mail
2 hours ago
- Globe and Mail
This AI ETF Could Turn $10,000 Into $40,000 by 2035
There's no denying it -- artificial intelligence (AI) is likely going to have a profound impact on the world over the long term. Entire industries could be altered. It's no wonder management teams are increasingly focused on ways to better position themselves for long-term success. From an investment perspective, perhaps it's starting to make sense that your portfolio should have some exposure to AI. Luckily, investors don't necessarily need to pick individual stocks if they want to benefit from the trend. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » There's one top AI exchange-traded fund (ETF) that could turn $10,000 into $40,000 by 2035. Continue reading to learn more about how to supercharge your portfolio for future success. Looking at the past and future In the last 10 years, the Invesco QQQ Trust (NASDAQ: QQQ) has generated a total return of 414% (as of June 3). This means that a $10,000 investment made in June 2015 would be worth $51,400 today. I don't think anyone in their right mind would complain with that kind of fantastic result. Even better, the expense ratio of 0.20% is a minimal cost to bear for that type of gain. There's no guarantee that past returns will repeat themselves going forward. Let's assume that there is a slowdown. Even so, I wouldn't be surprised if investors who put the same $10,000 in this ETF today see a fourfold gain in the next decade, resulting in a 15% annualized return. There's a lot of talk about how the stock market's current valuation is expensive. But consider that this has been the general narrative for a very long time. Yet that hasn't prevented equity markets from marching higher. The rise of passive investing, ongoing economic expansion, and dominance of tech-driven enterprises have all played a part. I'm fairly confident these trends will continue. Diversified exposure to artificial intelligence The Invesco QQQ Trust can be considered a top AI ETF, even though it contains 100 stocks in total. There is heavy concentration among the top positions, many of which have a meaningful AI focus. The so-called hyperscalers, most notably Amazon, Microsoft, and Alphabet, combined represent 18.9% of the Invesco QQQ Trust's asset base. These dominant companies have leading cloud computing platforms that offer a range of AI tools to their customers. They're collectively planning to spend hundreds of billions of dollars on capital expenditures in 2025 in an effort to bolster their technical infrastructure to better position themselves for an AI future. We can't forget about Nvidia, the biggest beneficiary thus far of the AI boom. It provides the graphics-processing units that power AI data centers, posting unbelievable revenue and profit growth. It's the second-largest holding in the Invesco QQQ Trust. Other top positions are Apple, Meta Platforms, Netflix, and Tesla. There's no doubt that AI has and will keep impacting these businesses in some way as well. Play the long game Investing correctly means having patience. While the AI craze has definitely made some investors rich in a short period of time, that's the wrong mindset to have. When buying the Invesco QQQ Trust, it's critical to keep the attention on the next decade and beyond. AI has the ability to revolutionize many parts of our economy, and this will all take time to play out. As of this writing, the Invesco QQQ Trust trades 2% off its peak. It might be tempting to wait for a bigger pullback to put money to work. However, I believe this is a flawed approach. It's a smart idea to invest early and often, letting compounding work its magic. Investing in this top AI ETF could work wonders for your portfolio between now and 2035. Should you invest $1,000 in Invesco QQQ Trust right now? Before you buy stock in Invesco QQQ Trust, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Invesco QQQ Trust wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor 's total average return is997% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Neil Patel has positions in Invesco QQQ Trust. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Netflix, Nvidia, and Tesla. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
